Skip to main content

Incyte Looks to Auction Off Genomics-Related Items

NEW YORK, May 17 (GenomeWeb News) - As part of its ongoing transition from a genomics company to a pharmaceutical firm, Incyte hopes to auction off many of its genomic research and laboratory equipment, GenomeWeb News has learned.


DoveBid, a capital asset auction and valuation company, has reported on its website that it will hold a webcast auction of various Incyte assets deemed "surplus to [the company's] continuing operations."


Among the items up for sale are a Cytomation S-1312 MoFlo high performance cell sorter, centrifuges, ultracentrifuges, and automatic pipetors, said DoveBid.


The auction will be held on June 15 at 9 a.m. Pacific Daylight Time. Details about the event can be found at here.


The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.